摘要
目的乳腺癌是发生于乳腺上皮或导管上皮的恶性肿瘤,近年来综合治疗手段的增加及方法的改进是促使乳腺癌死亡率下降的重要原因。其中,药物治疗是综合治疗的重要组成部分,随着分子生物学研究的发展,新药的出现、术后辅助化疗方案及剂量密集化疗的选择、新辅助化疗及维持化疗的应用,均提高了乳腺癌病人的生存率,为优化乳腺癌的治疗提供了更多新选择。
Breast cancer is the mammary epithelial or ductal epithelial malignancy. In recent years,owing to the in- crease and improvement of comprehensive treatment means, the breast cancer mortality declined. Among them, drug treat- ment is an important part of the comprehensive treatment. Along with the molecular biology research development, the occur- rence of new drug, postoperative adjuvant chemotherapy regimen and dose dense chemotherapy options,neoadjuvant chemo- therapy and the application of maintaining chemotherapy, all improve the breast cancer patient survival rate, providing more choice to optimize the treatment of breast cancer.
出处
《中南医学科学杂志》
CAS
2012年第5期509-513,536,共6页
Medical Science Journal of Central South China
关键词
乳腺癌
药物治疗
剂量密集化疗
新辅助化疗
维持治疗
靶向治疗
breast cancer
drug treatment
dose-dense chemotherapy
neoadjuvant chemotherapy
mainte-nance treatment
target therapy
作者简介
通讯作者：杨兰平，电话：0772-3195015，E-mail：yanglan8389@sina．com
